Insights on Clinical Trials

31. Evolving Landscape Of Payer Coverage For CGTs: Trends And Insights 1/20/2026

    Examine how proactive payer engagement and robust clinical evidence regarding comparative effectiveness and durability of response can overcome significant reimbursement barriers and enhance patient access.

32. What the FDA Looks For In Global Development Programs Today 1/16/2026

    Mastering the complexities of multi-regional clinical trials requires aligning global data with evolving regulatory expectations to ensure treatment consistency and successful drug approval.

33. The Growing Case For AI To Support Pharmacovigilance 1/14/2026

    Insights from the World Drug Safety Congress reveal how automation and AI streamline signal management and safety reporting while maintaining essential human oversight and ensuring regulatory compliance.

34. Accelerating Parkinson's Disease Clinical Research Through Recruitment Capabilities 1/14/2026

    Centralized PD trials cut variability, speed enrollment, and enable genetic stratification, delivering high‑quality data and faster progress from early‑phase research to late‑stage development.

35. Navigating The Enrollment Bottleneck In Early Oncology Trials 1/12/2026

    Slow oncology trial enrollment raises costs and delays progress. AI prescreening, patient-focused engagement, and early pharmacology studies help accelerate recruitment and optimize trial design.

36. Why Flexible, Collaborative Distribution Partners Matter For CGTs 1/9/2026

    Learn how collaborative distribution models manage reimbursement hurdles and complex delivery requirements to ensure patient access and long-term commercial success.

37. How A Strategic Bioanalysis CRO Partnership Empowers Sponsors 1/8/2026

    Choosing the right bioanalysis CRO is vital to avoid costly delays. Sponsors need evaluation strategies that prioritize proven quality, predictable timelines, and submission-ready data.

38. 6 Key Implications Of EU Clinical Trials Regulation 1/7/2026

    Centralized submissions, greater transparency, and stronger patient protections reshape EU clinical trials, impacting timelines, costs, and strategies for sponsors and CROs.

39. Why We Need To Look To The Future Of Clinical Trials 1/6/2026

    Explore how decentralized trial elements, community-focused site networks, and patient-centric infrastructure can improve recruitment, data quality, equity, and efficiency.

40. How In-Home Trials Can Shift The Pediatric Rare Disease Research Landscape 1/6/2026

    DCT solutions are not just about bringing the trial to the patient’s home and reducing logistical burdens, but also strengthening the family-researcher connection.